Literature DB >> 15346154

Postmarketing Results: Useful, But Proceed with Caution.

Jacqueline A. French.   

Abstract

Year:  2003        PMID： 15346154      PMCID： PMC321225          DOI： 10.1046/j.1535-7597.2003.03611.x

Source DB:  PubMed          Journal:  Epilepsy Curr        ISSN： 1535-7511            Impact factor:   7.500


× No keyword cloud information.
  6 in total

1.  Phase IV trials: a wolf in sheep's clothing?

Authors:  Michael D Privitera
Journal:  Ann Pharmacother       Date:  2003-05       Impact factor: 3.154

2.  Postmarketing surveillance of new antiepileptic drugs: the tribulations of trials.

Authors:  Jacqueline A French
Journal:  Epilepsia       Date:  2002-09       Impact factor: 5.864

Review 3.  Topiramate: a review of preclinical, pharmacokinetic, and clinical data.

Authors:  W E Rosenfeld
Journal:  Clin Ther       Date:  1997 Nov-Dec       Impact factor: 3.393

4.  Postmarketing experience with topiramate and cognition.

Authors:  W O Tatum; J A French; E Faught; G L Morris; J Liporace; A Kanner; S L Goff; L Winters; A Fix
Journal:  Epilepsia       Date:  2001-09       Impact factor: 5.864

5.  Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages. Topiramate YE Study Group.

Authors:  M Privitera; R Fincham; J Penry; R Reife; L Kramer; G Pledger; R Karim
Journal:  Neurology       Date:  1996-06       Impact factor: 9.910

6.  Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Topiramate YD Study Group.

Authors:  E Faught; B J Wilder; R E Ramsay; R A Reife; L D Kramer; G W Pledger; R M Karim
Journal:  Neurology       Date:  1996-06       Impact factor: 9.910
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.